Exchange: NASDAQ·Updated 04:10 PM EST
About RDHL
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a U.S. specialty biopharmaceutical company focused primarily on the development and commercialization of proprietary drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota®, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq®. RedHill’s key clinical late-stage development programs include: (i) RHB-102 (Bekinda®), with a potential UK MAA for oncology support (chemotherapy and radiotherapy induced nausea and vomiting (CINV/RINV)), positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and is Phase 2-ready for GLP-1/GIP-associated GI intolerance; (ii) opaganib (ABC294640), a first-in-class, orally administered, sphingosine kinase-2 (SPHK2) selective inhibitor with anticancer, anti-inflammatory and antiviral activity, targeting multiple indications including; prostate cancer, with an ongoing Phase 2 study in combination with darolutamide, neuroblastoma, in collaboration with Penn State University, and for which it has FDA Orphan Drug and Rare Pediatric Disease designations with potential for a Priority Review Voucher (PRV), multiple myeloma with US National Cancer Institute (NCI) grant-funded planned Phase1b/2 clinical studies in partnership with University of Oklahoma, and virus-induced acute respiratory distress syndrome (ARDS); (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a Phase 2-ready study for Crohn’s disease (based on RHB-104's positive U.S. Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and influenza and also targeting multiple cancer and inflammatory gastrointestinal diseases.